In reply

Tomasz M. Beer; Vinay Prasad

doi:10.1001/jamaoncol.2017.2349

In reply

Tomasz M. Beer, Vinay Prasad

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1588-1589
Number of pages	2
Journal	JAMA Oncology
Volume	3
Issue number	11
DOIs	https://doi.org/10.1001/jamaoncol.2017.2349
State	Published - Nov 2017

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2017.2349

Cite this

@article{45ae367796964010bf6316ad64c7efef,

title = "In reply",

author = "Beer, {Tomasz M.} and Vinay Prasad",

note = "Funding Information: Conflict of Interest Disclosures: Dr Beer reports receiving research funding from Astellas, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Janssen Research & Development, Medivation, OncoGenex, Sotio, and Theraclone Sciences; receiving consulting fees from AbbVie, AstraZeneca, Churchill Pharmaceuticals, Clovis Oncology, Dendreon, Janssen Biotech, Janssen Oncology, Janssen Research & Development, Johnson & Johnson, Janssen Japan, and F. Hoffmann-La Roche; and holding stock in Salarius Pharmaceuticals. No other disclosures are reported.",

year = "2017",

month = nov,

doi = "10.1001/jamaoncol.2017.2349",

language = "English (US)",

volume = "3",

pages = "1588--1589",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "11",

}

TY - JOUR

T1 - In reply

AU - Beer, Tomasz M.

AU - Prasad, Vinay

N1 - Funding Information: Conflict of Interest Disclosures: Dr Beer reports receiving research funding from Astellas, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Janssen Research & Development, Medivation, OncoGenex, Sotio, and Theraclone Sciences; receiving consulting fees from AbbVie, AstraZeneca, Churchill Pharmaceuticals, Clovis Oncology, Dendreon, Janssen Biotech, Janssen Oncology, Janssen Research & Development, Johnson & Johnson, Janssen Japan, and F. Hoffmann-La Roche; and holding stock in Salarius Pharmaceuticals. No other disclosures are reported.

PY - 2017/11

Y1 - 2017/11

UR - http://www.scopus.com/inward/record.url?scp=85042918588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042918588&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2017.2349

DO - 10.1001/jamaoncol.2017.2349

M3 - Letter

C2 - 28817761

AN - SCOPUS:85042918588

SN - 2374-2437

VL - 3

SP - 1588

EP - 1589

JO - JAMA Oncology

JF - JAMA Oncology

IS - 11

ER -

In reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this